WASHINGTON, D.C. (September 13, 2021) — Today, Scott Kuzner, PhD, is joining the Association for Accessible Medicines as Senior Director of Sciences and Regulatory Affairs at the Association for Accessible Medicines. He will be engaged in the development and oversight of AAM’s Sciences and Regulatory Affairs initiatives. Scott comes to AAM from the United States Pharmacopeial Convention (USP), where he served for more than a decade with increasing responsibility, most recently as Director, Board and Convention Operations.
As we wrap up GDUFA and BsUFA negotiations and begin the legislative review and approval processes, and move into the user fee implementation phases, this is a great time to bring Scott on board, said Senior Vice President, Sciences and Regulatory Affairs, David Gaugh.
We welcome Scott to our team and look forward to our continued strong collaboration with USP.
Scott holds a BA, MA and PhD from the University of Maryland.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.